CAVU BIOTHERAPIES Trademark

Trademark Overview

On Wednesday, April 6, 2016, a trademark application was filed for CAVU BIOTHERAPIES with the United States Patent and Trademark Office. The USPTO has given the CAVU BIOTHERAPIES trademark a serial number of 86984450. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, January 2, 2026. This trademark is owned by CAVU Biotherapies, Inc.. The CAVU BIOTHERAPIES trademark is filed in the Pharmaceutical Products, Treatment & Processing of Materials Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Preparation and dispensing of personalized immunotherapies, namely, cellular therapies for the treatment of cancers and autoimmune diseases; personalized white blood cell therapies; genetic testing for medical purposes; medical testing for diagnostic and treatment purposes; medical diagnostic monitoring and reporting services; medical testing for immune health assessment

Pharmaceutical and veterinary preparations for the treatment of cancer, namely, biological preparations for cell therapy, gene therapy, immunotherapy and the treatment and prevention of cancer; biological preparations for the treatment of cancer using immunotherapy, cell therapy and gene therapy; pharmaceutical and veterinary preparations using artificial T Cell receptors for the treatment of cancer using immunotherapy, cell therapy and gene therapy

Cellular cryopreservation services
cavu biotherapies

General Information

Serial Number86984450
Word MarkCAVU BIOTHERAPIES
Filing DateWednesday, April 6, 2016
Status710 - CANCELLED - SECTION 8
Status DateFriday, January 2, 2026
Registration Number5782003
Registration DateTuesday, June 18, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 7, 2017

Trademark Statements

Goods and ServicesPreparation and dispensing of personalized immunotherapies, namely, cellular therapies for the treatment of cancers and autoimmune diseases; personalized white blood cell therapies; genetic testing for medical purposes; medical testing for diagnostic and treatment purposes; medical diagnostic monitoring and reporting services; medical testing for immune health assessment
Goods and ServicesPharmaceutical and veterinary preparations for the treatment of cancer, namely, biological preparations for cell therapy, gene therapy, immunotherapy and the treatment and prevention of cancer; biological preparations for the treatment of cancer using immunotherapy, cell therapy and gene therapy; pharmaceutical and veterinary preparations using artificial T Cell receptors for the treatment of cancer using immunotherapy, cell therapy and gene therapy
NOT AVAILABLE"BIOTHERAPIES"
Goods and ServicesCellular cryopreservation services

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, January 2, 2026
Primary Code005
First Use Anywhere DateSunday, September 30, 2018
First Use In Commerce DateSunday, September 30, 2018
International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, January 2, 2026
Primary Code040
First Use Anywhere DateTuesday, July 31, 2018
First Use In Commerce DateTuesday, July 31, 2018
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, January 2, 2026
Primary Code044
First Use Anywhere DateSunday, September 30, 2018
First Use In Commerce DateSunday, September 30, 2018

Trademark Owner History

Party NameCOMPASS POINT GROUP, LLC
Party Type31 - New Owner After Registration
Legal Entity Type16 - Limited Liability Company
AddressNORTH PALM BEACH, FL 33408
Party NameCAVU Biotherapies, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressHouston, TX 77054
Party NameCAVU Biotherapies, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHouston, TX 77054
Party NameCAVU Biotherapies, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHouston, TX 77004

Trademark Events

Event DateEvent Description
Saturday, April 9, 2016NEW APPLICATION ENTERED
Monday, April 11, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 21, 2016ASSIGNED TO EXAMINER
Tuesday, July 26, 2016NON-FINAL ACTION WRITTEN
Tuesday, July 26, 2016NON-FINAL ACTION E-MAILED
Tuesday, July 26, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 25, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 25, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 25, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 31, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 15, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, February 17, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 7, 2017PUBLISHED FOR OPPOSITION
Tuesday, March 7, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 2, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, October 25, 2017SOU TEAS EXTENSION RECEIVED
Wednesday, October 25, 2017SOU EXTENSION 1 FILED
Wednesday, October 25, 2017SOU EXTENSION 1 GRANTED
Friday, October 27, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 30, 2018SOU TEAS EXTENSION RECEIVED
Monday, April 30, 2018SOU EXTENSION 2 FILED
Monday, April 30, 2018SOU EXTENSION 2 GRANTED
Wednesday, May 2, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 24, 2018SOU TEAS EXTENSION RECEIVED
Wednesday, October 24, 2018SOU EXTENSION 3 FILED
Wednesday, October 24, 2018SOU EXTENSION 3 GRANTED
Friday, October 26, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 3, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, December 3, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, April 26, 2019TEAS STATEMENT OF USE RECEIVED
Friday, April 26, 2019SOU TEAS EXTENSION RECEIVED
Friday, April 26, 2019TEAS REQUEST TO DIVIDE RECEIVED
Monday, May 13, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, April 26, 2019SOU EXTENSION 4 FILED
Monday, May 13, 2019SOU EXTENSION 4 GRANTED
Friday, April 26, 2019DIVISIONAL REQUEST RECEIVED
Monday, May 13, 2019DIVISIONAL PROCESSING COMPLETE
Friday, April 26, 2019USE AMENDMENT FILED
Monday, May 13, 2019STATEMENT OF USE PROCESSING COMPLETE
Monday, May 13, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, May 14, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, May 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2019REGISTERED-PRINCIPAL REGISTER
Friday, September 27, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, September 27, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 29, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, July 29, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 29, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 29, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, July 29, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 29, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, June 4, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Tuesday, June 4, 2024WITHDRAWAL OF ATTORNEY GRANTED
Tuesday, June 18, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, October 2, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, January 2, 2026CANCELLED SEC. 8 (6-YR)

Related Keywords

biotherapies cavu therapy treatment cell medical cancer preparations using gene immunotherapy testing